Peter J. Bailey
YOU?
Author Swipe
View article: The landscape of long noncoding RNA during cutaneous squamous cell carcinoma progression
The landscape of long noncoding RNA during cutaneous squamous cell carcinoma progression Open
Background Cutaneous squamous cell carcinoma (cSCC) is a common cancer with a high morbidity rate and poor prognosis for metastatic disease. Disease may progress from premalignant actinic keratosis to invasive and metastatic cSCC, but it i…
View article: MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC
MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC Open
Intratumour heterogeneity and phenotypic plasticity drive tumour progression and therapy resistance1,2. Oncogene dosage variation contributes to cell-state transitions and phenotypic heterogeneity3, thereby providing a substrate for somati…
View article: Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial Open
PURPOSE The ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine (GemCap) produced longer overall survival (OS) than gemcitabine monotherapy. Subsequently, the PRODIGE24-CCTG PA.6 trial showed even longer survi…
View article: Tumour plasticity and tumour microenvironment interactions as potential immunologic targets for pancreatic cancer treatment
Tumour plasticity and tumour microenvironment interactions as potential immunologic targets for pancreatic cancer treatment Open
Pancreatic ductal adenocarcinoma (PDAC) is a malignant cancer with a high mortality and limited treatment options. Systemic chemotherapy remains the only approach for improving survival in patients with unresectable locally advanced and/or…
View article: Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response
Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response Open
Metavert as a single agent and in combination with irinotecan offers novel strategies for treating pancreatic cancer.
View article: The pluripotency factor NANOG contributes to mesenchymal plasticity and is predictive for outcome in esophageal adenocarcinoma
The pluripotency factor NANOG contributes to mesenchymal plasticity and is predictive for outcome in esophageal adenocarcinoma Open
Background Despite the advent of neoadjuvant chemoradiotherapy (CRT), overall survival rates of esophageal adenocarcinoma (EAC) remain low. A readily induced mesenchymal transition of EAC cells contributes to resistance to CRT. Methods In …
View article: Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer
Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer Open
Tumors weakly infiltrated by T lymphocytes poorly respond to immunotherapy. We aimed to unveil malignancy-associated programs regulating T cell entrance, arrest, and activation in the tumor environment. Differential expression of cell adhe…
View article: AmpliconSuite: an end-to-end workflow for analyzing focal amplifications in cancer genomes
AmpliconSuite: an end-to-end workflow for analyzing focal amplifications in cancer genomes Open
Focal amplifications in the cancer genome, particularly extrachromosomal DNA (ecDNA) amplifications, are emerging as a pivotal event in cancer progression across diverse cancer contexts, presenting a paradigm shift in our understanding of …
View article: Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC
Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC Open
Objective The dysregulation of the axon guidance pathway is common in pancreatic ductal adenocarcinoma (PDAC), yet our understanding of its biological relevance is limited. Here, we investigated the functional role of the axon guidance cue…
View article: Pan-cancer evolution signatures link clonal expansion to dynamic changes in the tumour immune microenvironment
Pan-cancer evolution signatures link clonal expansion to dynamic changes in the tumour immune microenvironment Open
Cancer is an evolutionary process characterised by profound intra-tumour heterogeneity. Intra-tumour heterogeneity can be quantified using in silico estimates of cancer cell fractions of tumour-specific somatic mutations. Here we demonstra…
View article: Personalized treatment in localized pancreatic cancer
Personalized treatment in localized pancreatic cancer Open
Summary The treatment elements used for pancreatic ductal adenocarcinoma (PDAC) include surgical resection, systemic cytotoxic agents, and targeted drugs. For second- and third-line therapies in PDAC, approximately 15% of patients have act…
View article: ecDNA amplification of<i>MYC</i>drives intratumor copy-number heterogeneity and adaptation to stress in PDAC
ecDNA amplification of<i>MYC</i>drives intratumor copy-number heterogeneity and adaptation to stress in PDAC Open
Intratumor heterogeneity and phenotypic plasticity drive tumour progression and therapy resistance. Oncogene dosage variation contributes to cell state transitions and phenotypic heterogeneity, thereby providing a substrate for somatic evo…
View article: Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC Open
Neoadjuvant chemotherapy can improve the survival of individuals with borderline and unresectable pancreatic ductal adenocarcinoma; however, heterogeneous responses to chemotherapy remain a significant clinical challenge. Here, we performe…
View article: Driver gene combinations dictate cutaneous squamous cell carcinoma disease continuum progression
Driver gene combinations dictate cutaneous squamous cell carcinoma disease continuum progression Open
The molecular basis of disease progression from UV-induced precancerous actinic keratosis (AK) to malignant invasive cutaneous squamous cell carcinoma (cSCC) and potentially lethal metastatic disease remains unclear. DNA sequencing studies…
View article: Molecular Subtypes and Clinical Applications
Molecular Subtypes and Clinical Applications Open
Molecular profiling has transformed our understanding of pancreatic ductal adenocarcinoma (PDAC) by characterizing germline predispositions, recurrent genetic alterations, intrinsic transcriptional subtypes, metastatic progression, and tum…
View article: Supplementary Information from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression
Supplementary Information from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression Open
Supplementary figure legends and methods.
View article: Figure S1 from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression
Figure S1 from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression Open
Prolactin does not promote activation of Jak2 signaling pathway in BxPC3 cell line, which lacks PRLR expression.
View article: Figure S2 from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression
Figure S2 from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression Open
The pancreas of adult prolactin deficient mice display no obvious abnormalities.
View article: Data from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression
Data from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression Open
Pancreatic ductal adenocarcinoma (PDAC) is associated with significant fibrosis. Recent findings have highlighted the profibrotic activity of tissue-resident macrophages in the pancreatic cancer microenvironment. Here, we show that neoplas…
View article: Data from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression
Data from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression Open
Pancreatic ductal adenocarcinoma (PDAC) is associated with significant fibrosis. Recent findings have highlighted the profibrotic activity of tissue-resident macrophages in the pancreatic cancer microenvironment. Here, we show that neoplas…
View article: Figure S2 from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression
Figure S2 from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression Open
The pancreas of adult prolactin deficient mice display no obvious abnormalities.
View article: Figure S1 from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression
Figure S1 from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression Open
Prolactin does not promote activation of Jak2 signaling pathway in BxPC3 cell line, which lacks PRLR expression.
View article: Figure S3 from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression
Figure S3 from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression Open
Total FAK1 and STAT3 are present in KC;Prl-/- PanINs.
View article: Figure S3 from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression
Figure S3 from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression Open
Total FAK1 and STAT3 are present in KC;Prl-/- PanINs.
View article: Supplementary Information from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression
Supplementary Information from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression Open
Supplementary figure legends and methods.
View article: Author Correction: The landscape of viral associations in human cancers
Author Correction: The landscape of viral associations in human cancers Open
Correction to: Nature Genetics, published online 05 February 2020. In the published version of this paper, the members of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium were listed in the Supplementary Information; however, th…
View article: Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer
Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer Open
[This corrects the article DOI: 10.3389/fcell.2021.743908.].